|
|
Article: Investigational Protease Inhibitor Fortovase(TM) (saquinavir) Compares Favorably in First Head-to-Head Study
- Article from:
- PR Newswire
- Article date:
- September 29, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Viral Load Decreases Equal to Crixivan;
CD4 Counts Higher With FORTOVASE at 12 Weeks
TORONTO, Sept. 29 /PRNewswire/ -- Data presented today from the first-ever head-to-head trial comparing two HIV protease inhibitors show that FORTOVASE(TM), an investigational soft gel formulation of saquinavir, has similar antiviral activity as the widely used Crixivan(R) (indinivir) when either drug is taken in combination with AZT and 3TC. The data from a study of 44 patients also show that FORTOVASE (n=16) increased CD4 counts more than Crixivan (n=14) after 12 weeks. The data were presented at the 37th Interscience Conference on ...